They hypothesized that if the genetic marker was associated with PSA level and not prostate cancer, then the effect estimate would be greatest when using ‘low’ PSA controls and close to the null when using ‘high’ PSA controls. This evidence concerns the gene KLK3 and prostate carcinoma.